Ester Pungolino

3.8k total citations · 1 hit paper
39 papers, 2.0k citations indexed

About

Ester Pungolino is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Ester Pungolino has authored 39 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hematology, 27 papers in Genetics and 8 papers in Molecular Biology. Recurrent topics in Ester Pungolino's work include Chronic Myeloid Leukemia Treatments (18 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Acute Myeloid Leukemia Research (10 papers). Ester Pungolino is often cited by papers focused on Chronic Myeloid Leukemia Treatments (18 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Acute Myeloid Leukemia Research (10 papers). Ester Pungolino collaborates with scholars based in Italy, United States and Spain. Ester Pungolino's co-authors include Enrica Morra, Francesco Passamonti, Mario Cazzola, Elisa Rumi, Mario Lazzarino, Cristiana Pascutto, Alessandro M. Vannucchi, Ayalew Tefferi, Marianna Caramella and Paola Guglielmelli and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The American Journal of Medicine.

In The Last Decade

Ester Pungolino

39 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

2009 623 citations Francesco Passamonti, Alessandro M. Vannucchi et al. Blood profile →

Peers

Countries citing papers authored by Ester Pungolino

Since Specialization

Citations

This map shows the geographic impact of Ester Pungolino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ester Pungolino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ester Pungolino more than expected).

Fields of papers citing papers by Ester Pungolino

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ester Pungolino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ester Pungolino. The network helps show where Ester Pungolino may publish in the future.

Co-authorship network of co-authors of Ester Pungolino

This figure shows the co-authorship network connecting the top 25 collaborators of Ester Pungolino. A scholar is included among the top collaborators of Ester Pungolino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ester Pungolino. Ester Pungolino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bosutinib Treatment of Chronic Myeloid Leukemia in Lombardy 2024 ·Acta Haematologica ·Alessandra Iurlo, Cristina Bucelli, Tamara Intermesoli, Chiara Elena, (unknown), (unknown), (unknown), Margherita Maffioli, Nicola Orofino, Francesca Lunghi, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Daniele Cattaneo, Ester Pungolino, Carlo Gambacorti‐Passerini	1
2	Occurrence of L1M Elements in Chromosomal Rearrangements Associated to Chronic Myeloid Leukemia (CML): Insights from Patient-Specific Breakpoints Characterization 2023 ·Genes ·Alberto L’Abbate, (unknown), Ester Pungolino, (unknown), Roberto Valli, Annalisa Frattini, Matteo Barcella, Francesco Acquati, Rolland Reinbold, Lucy Costantino, F. Ferrara, Alessandra Trojani, Mario Ventura, Giovanni Porta, Roberto Cairoli	1
3	Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10⁹/L to <100 × 10⁹/L) at baseline: the final analysis of EXPAND 2022 ·Therapeutic Advances in Hematology ·Paola Guglielmelli, Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Minghui Duan, Haitao Meng, Ling Pan, Guangsheng He, Srđan Verstovšek, Françoise Boyer, Fiorenza Barraco, Dietger Niederwieser, Ester Pungolino, (unknown), Claire Harrison, (unknown), (unknown), (unknown), (unknown), Peter A.W. te Boekhorst, Heinz Gisslinger	9
4	Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study 2020 ·Blood Research ·Maria Gemelli, Elena Maria Elli, Chiara Elena, Alessandra Iurlo, Tamara Intermesoli, Margherita Maffioli, Ester Pungolino, (unknown), Mariella D’Adda, Francesca Lunghi, (unknown), Nicola Polverelli, Marianna Rossi, (unknown), Elisa Bono, Cristina Bucelli, Francesco Passamonti, Laura Antolini, Carlo Gambacorti‐Passerini	6
5	ENESTPath: A Phase 3 Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with Imatinib: 24-Month Analysis of the First 300 Patients in the Induction/Consolidation Phase 2016 ·Blood ·Delphine Réa, Gianantonio Rosti, Nicholas C.P. Cross, Andrzej Hellmann, Dietger Niederwieser, Ester Pungolino, Franca Falzetti, Patrizia Pregno, Ester Orlandi, Antônio-Carlos G. de Almeida, Árpád Illés, (unknown), (unknown), (unknown), Seema Shah, Giuseppe Saglio, Juan Luis Steegmann, Michele Baccarani	13
6	EXPAND: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Low Platelet Counts (50 × 109/L to 99 × 109/L) at Baseline 2015 ·Blood ·Alessandro M. Vannucchi, Heinz Gisslinger, Claire Harrison, Haifa Kathrin Al‐Ali, Ester Pungolino, Jean‐Jacques Kiladjian, (unknown), Franck E. Nicolini, Shuyuan Mo, (unknown), Prashanth Gopalakrishna, Peter A. te Boekhorst	7
7	Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase 2015 ·Blood ·Delphine Réa, Gianantonio Rosti, Nicholas C.P. Cross, (unknown), Dietger Niederwieser, Ester Pungolino, Franca Falzetti, Patrizia Pregno, Ester Orlandi, António Almeida, Árpád Illés, (unknown), Luca Dezzani, (unknown), Chiara Costantini, (unknown), Giuseppe Saglio, Juan Luis Steegmann, Michele Baccarani	8
8	Transient Massive Lymphoid Bone Marrow Infiltrate Developing during Therapy with the Tyrosine Kinase Inhibitors Imatinib and Nilotinib: Report of 2 Patients. 2007 ·Blood ·Ester Pungolino, Silvia Cantoni, (unknown), Livio Gargantini, Marianna Caramella, Sara Miqueleiz, Alessandra Tedeschi, (unknown), (unknown), (unknown), (unknown), (unknown), Enrica Morra	1
9	Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 2004 ·The American Journal of Medicine ·Francesco Passamonti, Elisa Rumi, Ester Pungolino, Lucia Malabarba, Paola Bertazzoni, (unknown), Ester Orlandi, Luca Arcaini, Ercole Brusamolino, Cristiana Pascutto, Mario Cazzola, Enrica Morra, Mario Lazzarino	317
10	Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H 2003 ·Leukemia ·Marco Montillo, Alessandra Tedeschi, Valentina Rossi, Roberto Cairoli, Ester Pungolino, (unknown), Anna Maria Cafro, Giovanna D’Avanzo, (unknown), Bruno Brando, Barbara Scarpati, Silvio Veronese, Enrica Morra	34
11	Late Response to Cyclosporine in Refractory Thrombotic Thrombocytopenic Purpura 2002 ·International Journal of Hematology ·Annamaria Nosari, Patrizia Bernuzzi, (unknown), Ester Pungolino, Giuliana Muti, Antônio Rossi, Enrica Morra	7
12	The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia 2000 ·European Journal of Cancer ·R Perego, Melania Costantini, (unknown), Livio Gargantini, Cristina Bianchi, Ester Pungolino, Ermanna Rovida, Enrica Morra	52
13	Hepato-splenic ?? T-cell lymphoma: A rare entity mimicking the hemophagocytic syndrome 1999 ·American Journal of Hematology ·A. Nosari, (unknown), Andrea Biondi, (unknown), Luca Santoleri, (unknown), Giuliana Muti, Ester Pungolino, Livio Gargantini, Enrica Morra	36
14	Twelve Years Experience with High-Dose Therapy and Autologous Stem Cell Transplantation for High-Risk Hodgkin's Disease Patients in First Remission After MOPP/ABVD Chemotherapy 1996 ·Leukemia & lymphoma ·Carella Am, (unknown), Ester Pungolino, Enrica Lerma, Francesco Frassoni, Edoardo Rossi, Domenico Giordano, D Occhini, Anna Gatti, (unknown), Mauro Spriano, S Nati, (unknown), (unknown), R. Vimercati, (unknown), Massimo Federico	29
15	PBSC collection from G-CSF primed donors 1996 ·Transfusion Science ·M. Valbonesi, N. Pollicardo, P. Carlier, G. Florio, (unknown), Ester Pungolino, Federica Benvenuto, O Figari	9
16	Philadelphia‐chromosome‐negative peripheral blood stem cells can be mobilized in the early phase of recovery after a myelosuppressive chemotherapy in Philadelphia‐chromosome‐positive acute lymphoblastic leukaemia 1995 ·British Journal of Haematology ·Angelo Michele Carella, Francesco Frassoni, N. Pollicardo, Ester Pungolino, (unknown), (unknown), Monica Soracco, Domenico Giordano, O Figari, Federica Benvenuto, G. Florio, P. Carlier, M. Valbonesi	22
17	Idarubicin, Intermediate-Dose Cytarabine, Etoposide, and Granulocyte-Colony-Stimulating Factor Are Able to Recruit CD34 ⁺ /HLA-DR ^- Cells During Early Hematopoietic Recovery in Accelerated and Chronic Phases of Chronic Myeloid Leukemia 1994 ·Journal of Hematotherapy ·Angelo Michele Carella, Francesco Frassoni, Marina Podestà, Ester Pungolino, N. Pollicardo, (unknown), Monica Soracco	17
18	Selective overshoot of ph&hyphen;negative blood hemopoietic cells after intensive idarubicin&hyphen;containing regimen and their repopulating capacity after reinfusion 1993 ·Stem Cells ·Angelo Michele Carella, Marina Podestà, Francesco Frassoni, Ester Pungolino, N. Pollicardo, (unknown), (unknown), Federica Benvenuto, O Figari, Domenico Giordano, Alberto M. Marmont, M. Valbonesi, G. Lercari, Vito Vitale, (unknown), P. Carlier, Andrea Gallamini, Giuseppe Saglio	12
19	Autologous Unpurged Bone Marrow Transplantation for Acute Non Lymphoblastic Leukemia in First Remission 1991 ·Leukemia & lymphoma ·Angelo Michele Carella, S Nati, P. Carlier, (unknown), Domenico Giordano, A Congiu, Gino Santini, D Scarpati, Salvina Barra, Renzo Corvò, Vito Vitale, (unknown), R Cerri, Marco Risso, Mauro Spriano, R. Vimercati, Ester Pungolino, Andrea Bacigalupo, E Damasio	3
20	Idarubicin in combination with intermediate‐dose cytarabine in the treatment of refractory or relapsed acute leukemias* 1989 ·European Journal Of Haematology ·Angelo Michele Carella, Ester Pungolino, Gabriella Piatti, (unknown), S Nati, Mauro Spriano, Domenico Giordano, (unknown), E Damasio	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact